BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023.

Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2023 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 27, 2023.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced it has expanded its ophthalmic portfolio with the launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, an AB-rated generic equivalent to the branded product Combigan®.*

Disc Medicine, Inc. (NASDAQ:IRON) announced today it will host a virtual KOL investor event on Tuesday, April 25, 2023, at 1:00 pm ET/ 10:00 am PT to provide an overview of erythropoietic protoporphyria (EPP), a rare, severe disease caused by mutations in the heme biosynthesis pathway.

Peel Therapeutics announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis.

Certis Oncology Solutions (“Certis”) today announced the launch of CertisAI™, a new predictive medicine platform that utilizes big data, statistical algorithms, and machine learning to predict drug efficacy based on gene expression biomarkers.

On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharmaceuticals) announced that its proprietary anti-influenza agent ZX-7101A met the primary endpoint with excellent safety and efficacy profiles in phase 2 clinical study for the treatment of acute uncomplicated influenza in adults.

BioCareSD, a specialty distributor of life-saving therapies, today announced that ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, is now available through their network.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that it will participate in four upcoming investor conferences.

SAB Biotherapeutics announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.